the same survey 80% approved of APOE*4 testing of a 50 year-old man whose mother has Alzheimer’s disease and who is contemplating a major 10-year financial investment; and 60% approved testing a 21 year-old man whose grandfather died of Alzheimer’s disease and who will give $10 million from his inheritance to Alzheimer’s research if he is predisposed himself (Mrazek et al., 2007). Again, the putative utility of the information to be obtained appears to play an important role in support for testing.
